Cited by 955Parkinson's Disease Mechanisms and TreatmentsNerve injury and regenerationNuclear Receptors and Signaling

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Functional recovery in parkinsonian monkeys treated with GDNF

Gash, Don M., Zhang, Zhiming, Ovadia, Aliza, Cass, Wayne A., Yi, Ai, Simmerman, Linda, Russell, Deborah, Martin, David, Lapchak, Paul A., Collins, Frank, Hoffer, Barry J., Gerhard, Greg A.·1996·Nature

DOI 10.1038/380252a0

Open this paper in CoChat — free account

Abstract

Parkinson's disease results from the progressive degeneration of dopamine neurons that innervate the striatum. In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons. Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally in rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.

Integrity signals

Registry

Crossref · 10.1038/380252a0

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
Self-citation
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
Self-citation
New stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 850
Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
A consideration of neural counting methods
Coggeshall, R. E. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90339-a · Cited by 540
Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo
Hoffer, B. J., Hoffman, A. F., Bowenkamp, K., Huettl, P. F., Hudson, J., Martin, D., Lin, L.-F. H., & Gerhardt, G. A. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90218-6 · Cited by 453
Self-citation
GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
Kearns, C. M., & Gash, D. M. (1995) · Brain Research · doi:10.1016/0006-8993(94)01366-p · Cited by 379
Self-citation
Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 2

Jellinger, K. Adv. Neurol. 45, 1–18 (1986).
Hornykiewicz, O. & Kish, S. J. Adv. Neurol. 45, 19–34 (1986).

Sorted by citations

Parkinson's Disease
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Parkinson's Disease
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
Parkinson's disease
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,361
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J. L., Chen, E., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Renal agenesis and the absence of enteric neurons in mice lacking GDNF
Sánchez, M. P., Silos‐Santiago, I., Frisén, J., He, B., Lira, S. A., & Barbacid, M. (1996) · Nature · doi:10.1038/382070a0 · Cited by 1,196
Defects in enteric innervation and kidney development in mice lacking GDNF
Pichel, J. G., Shen, L., SHENG, H. Z., Granholm, A., Drago, J., Grinberg, A., Lee, E. J., Huang, S. P., Saarma, M., Hoffer, B. J., et al. (1996) · Nature · doi:10.1038/382073a0 · Cited by 1,153
Self-citation
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 947
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C., Jankovic, J. J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M. A., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 816
Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 835
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739
Functional and pathophysiological models of the basal ganglia
Wichmann, T., & DeLong, M. R. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80024-9 · Cited by 724
An algorithm (decision tree) for the management of Parkinson’s disease (2001):
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 724
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
Marks, W. J., Bartus, R. T., Siffert, J. O., Davis, C. S., Lozano, A. M., Boulis, N. M., Vitek, J. L., Stacy, M. A., Turner, D. A., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 703
Experimental models of Parkinson's disease
Beal, M. F. (2001) · Nature reviews. Neuroscience · doi:10.1038/35072550 · Cited by 645
Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy
Choi-Lundberg, D. L., Lin, Q., Chang, Y., Chiang, Y. L., Hay, C. M., Mohajeri, H. M., Davidson, B. L., & Bohn, M. C. (1997) · Science · doi:10.1126/science.275.5301.838 · Cited by 622
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor
Batchelor, P., Liberatore, G. T., Wong, J. Y. F., Porritt, M. J., Frerichs, F., Donnan, G. A., & Howells, D. W. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-05-01708.1999 · Cited by 576
The role of neuronal growth factors in neurodegenerative disorders of the human brain
Connor, B. J., & Dragunow, M. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00004-6 · Cited by 538
Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra
Howells, D. W., Porritt, M. J., Wong, J. Y. F., Batchelor, P. E., Kalnins, R., Hughes, A. J., & Donnan, G. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7483 · Cited by 513
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_19 · Cited by 518
Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin
Milbrandt, J., de Sauvage, F. J., Fahrner, T. J., Baloh, R. H., Leitner, M. L., Tansey, M. G., Lampe, P. A., Heuckeroth, R. O., Kotzbauer, P. T., Simburger, K. S., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80453-5 · Cited by 494
Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain
Siegel, G. J., & Chauhan, N. B. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00030-8 · Cited by 492
Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease
Lang, A. E., Lozano, A. M., Montgomery, E. B., Duff, J., Tasker, R. R., & Hutchinson, W. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371503 · Cited by 479
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line—derived neurotrophic factor
Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M., Kryscio, R. J., & Young, B. A. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0216 · Cited by 474
Self-citation
Fetal Nigral Transplantation as a Therapy for Parkinson's Disease
Olanow, C. W., & Fahn, S. (2006) · Springer eBooks · doi:10.1007/0-387-32823-8_6 · Cited by 415
Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease
Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., & Nagatsu, T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00463-2 · Cited by 404
Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study
Patel, N. K., Bunnage, M., Plaha, P., Svendsen, C. N., Heywood, P. G., & Gill, S. S. (2005) · Annals of Neurology · doi:10.1002/ana.20374 · Cited by 384
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease
Maswood, N., Young, J., Tilmont, E. M., Zhang, Z., Gash, D. M., Gerhardt, G. A., Grondin, R., Roth, G. S., Mattison, J. A., Lane, M. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405831102 · Cited by 383
Self-citation
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 371
Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes
Chen, P.-S., Peng, G.-S., Li, G., Yang, S., Wu, X., Wang, C. C., Wilson, B. C., Lu, R.-B., Gean, P.-W., Chuang, D.-M., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001893 · Cited by 356
TrnR2, a Novel Receptor That Mediates Neurturin and GDNF Signaling through Ret
Baloh, R. H., Tansey, M. G., Golden, J. P., Creedon, D. J., Heuckeroth, R. O., Keck, C. L., Zimonjic, D. B., Popescu, N. C., Johnson, E. M., & Milbrandt, J. (1997) · Neuron · doi:10.1016/s0896-6273(00)80318-9 · Cited by 351
Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells
Redmond, D. E., Bjugstad, K. B., Teng, Y. D., Ourednik, V., Ourednik, J., Wakeman, D. R., Parsons, X. H., Gonzalez, R., Blanchard, B. C., Kim, S. U., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704091104 · Cited by 341
Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons
Horger, B. A., Nishimura, M. C., Armanini, M. P., Wang, L.-C., Poulsen, K. T., Rosenblad, C., Kirik, D., Moffat, B., Simmons, L., Johnson, E., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-13-04929.1998 · Cited by 338
Absolute requirement of GDNF for adult catecholaminergic neuron survival
Pascual, A., Hidalgo‐Figueroa, M., Piruat, J. I., Pintado, C. O., Gómez-Díaz, R., & López‐Barneo, J. (2008) · Nature Neuroscience · doi:10.1038/nn.2136 · Cited by 332
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats
Mandel, R. J., Spratt, S. K., Snyder, R. O., & Leff, S. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.14083 · Cited by 328
The role of glial cells in Parkinsonʼs disease
Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00009 · Cited by 326
Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models
Steiner, J. P., Hamilton, G. S., Ross, D. T., Valentine, H. L., Guo, H., Connolly, M. A., Liang, S., Ramsey, C., Li, J.-H. J., Huang, W., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2019 · Cited by 324
Anatomy of the dopamine system in the basal ganglia
Smith, Y., & Kieval, J. Z. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00023-9 · Cited by 320
Glial Cell Line-Derived Neurotrophic Factor Protects against Ischemia-Induced Injury in the Cerebral Cortex
Wang, Y., Lin, S., Chiou, A. L., Williams, L. R., & Hoffer, B. J. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-11-04341.1997 · Cited by 314
Self-citation
How to make a midbrain dopaminergic neuron
Arenas, E., Denham, M., & Villaescusa, C. (2015) · Development · doi:10.1242/dev.097394 · Cited by 321
Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease
Åkerud, P., Canals, J. M., Snyder, E. Y., & Arenas, E. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08108.2001 · Cited by 303
Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease
Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.-J., Mallet, J., & Horellou, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8818 · Cited by 297
Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins
Sanicola, M., Hession, C. A., Worley, D. S., Carmillo, P., Ehrenfels, C. W., Walus, L. R., Robinson, S., Jaworski, G. J., Wei, H., Tizard, R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6238 · Cited by 295
Self-Inactivating Lentiviral Vectors with Enhanced Transgene Expression as Potential Gene Transfer System in Parkinson's Disease
Déglon, N., Tseng, J., Bensadoun, J. C., Zurn, A. D., Arsenijévic, Y., de Almeida, L. P., Zufferey, R., Trono, D., & Aebischer, P. (2000) · Human Gene Therapy · doi:10.1089/10430340050016256 · Cited by 298
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 296
Localized striatal delivery of GDNF as a treatment for Parkinson disease
Kirik, D., Georgievska, B., & Björklund, A. (2004) · Nature Neuroscience · doi:10.1038/nn1175 · Cited by 289
Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: A double‐blind, randomized, controlled trial
Olanow, C. W., Bartus, R. T., Baumann, T. L., Factor, S. A., Boulis, N. M., Stacy, M. A., Turner, D. A., Marks, W. J., Larson, P., Starr, P. A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24436 · Cited by 287
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Charvin, D., Medori, R., Hauser, R. A., & Rascol, O. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.136 · Cited by 294
Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease
Whone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dharia, S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N. U., et al. (2019) · Brain · doi:10.1093/brain/awz023 · Cited by 282
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys
Grondin, R., Zhang, Z., Ai, Y., Cass, W. A., Maswood, N., Andersen, A. H., Elsberry, D. D., Klein, M. C., Gerhardt, G. A., & Gash, D. M. (2002) · Brain · doi:10.1093/brain/awf234 · Cited by 280
Self-citation
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O. S., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson-Lewis, V. R., & Przedborski, S. (2002) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 276
Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease
Voutilainen, M. H., Bäck, S., Pörsti, E., Toppinen, L., Lindgren, L., Lindholm, P., Peränen, J., Saarma, M., & Tuominen, R. K. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0833-09.2009 · Cited by 269
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.1.139 · Cited by 275
Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system
Taraviras, S. L., Marcos-Gutierrez, C. V., Durbec, P. L., Jani, H., Grigoriou, M. E., Sukumaran, M., Wang, L.-C., Hynes, M., Raisman, G., & Pachnis, V. (1999) · Development · doi:10.1242/dev.126.12.2785 · Cited by 263
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
Rosenblad, C., Kirik, D., Devaux, B., Moffat, B., PHILLIPS, H. S., & Björklund, A. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00566.x · Cited by 261
Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease
Winkler, C., Sauer, H., Lee, C. S., & Björklund, A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-22-07206.1996 · Cited by 258
Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 251
Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease
Björklund, A., Rosenblad, C., Winkler, C., & Kirik, D. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0151 · Cited by 247
Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats
Wang, J., Wu, J.-N., Cherng, T.-L., Hoffer, B. J., Chen, H.-H., Borlongan, C. V., & Wang, Y. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02450-7 · Cited by 242
Self-citation
Dental pulp cells provide neurotrophic support for dopaminergic neurons and differentiate into neurons in vitro; implications for tissue engineering and repair in the nervous system
Nosrat, I. V., Smith, C. A., Mullally, P., Olson, L., & Nosrat, C. A. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03314.x · Cited by 242
Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis
Hansford, J. R., & Mulligan, L. M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.817 · Cited by 237
NURR1 in Parkinson disease—from pathogenesis to therapeutic potential
Decressac, M., Volakakis, N., Björklund, A., & Perlmann, T. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.209 · Cited by 234
Biology of GDNF and its receptors — Relevance for disorders of the central nervous system
Ibáñez, C. F., & Andressoo, J. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.01.021 · Cited by 234
Ablative Surgery and Deep Brain Stimulation for Parkinson's Disease
Starr, P. A., Vitek, J. L., & Bakay, R. A. E. (1998) · Neurosurgery · doi:10.1097/00006123-199811000-00001 · Cited by 230
Glial Cell Line-Derived Neurotrophic Factor Requires Transforming Growth Factor-β for Exerting Its Full Neurotrophic Potential on Peripheral and CNS Neurons
KRIEGLSTEIN, K. G., Henheik, P., Farkas, L. M., Jászai, J., Galter, D., Krohn, K., & Unsicker, K. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09822.1998 · Cited by 228
Cell death mechanisms in Parkinson's disease
Jellinger, K. A. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050001 · Cited by 227
Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system
Nosrat, C. A., Tomac, A. C., Lindqvist, E., Lindskog, S. F., Humpel, C., Strömberg, I., Ebendal, T., Hoffer, B. J., & Olson, L. (1996) · Cell and Tissue Research · doi:10.1007/s004410050688 · Cited by 226
Self-citation
Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain
Peden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222
Involvement of basal ganglia transmitter systems in movement initiation
Hauber, W. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00041-0 · Cited by 222
Redox imbalance
Berg, D., Youdim, M. B. H., & Riederer, P. F. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0976-5 · Cited by 221
Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration
Palfi, S., Leventhal, L., Chu, Y., Ma, S. Y., Emborg, M. E., Bakay, R. A. E., Déglon, N., Hantraye, P., Aebischer, P., & Kordower, J. H. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-12-04942.2002 · Cited by 215
Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach
Bézard, E., & Gross, C. E. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00006-9 · Cited by 224
Enriched Environment Confers Resistance to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Cocaine: Involvement of Dopamine Transporter and Trophic Factors
Bézard, E., Doveró, S., Belin, D., Duconger, S., Jackson-Lewis, V. R., Przedborski, S., Piazza, P. V., Gross, C. E., & Jaber, M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-35-10999.2003 · Cited by 213
Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain
Chauhan, N. B., Siegel, G. J., & Lee, J. M. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00115-6 · Cited by 207
Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6‐OHDA lesion model depends on the site of administration of the trophic factor
Kirik, D., Rosenblad, C., & Björklund, A. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00274.x · Cited by 206
Protection by Synergistic Effects of Adenovirus-Mediated X-Chromosome-Linked Inhibitor of Apoptosis and Glial Cell Line-Derived Neurotrophic Factor Gene Transfer in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
Eberhardt, O., von Coelln, R., Kügler, S., Lindenau, J. H., Rathke‐Hartlieb, S., Gerhardt, E., Haid, S., Isenmann, S., Gravel, C., Srinivasan, A. N., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09126.2000 · Cited by 206
Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse.
Frasson, M., Picaud, S. A., Léveillard, T., Simonutti, M., Mohand‐Saïd, S., Dreyfus, H., Hicks, D., & Sabel, J. L. (1999) · PubMed · Cited by 202
Presynaptic regulation of dopaminergic neurotransmission
Schmitz, Y., Benoit‐Marand, M., Gonon, F., & Sulzer, D. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02050.x · Cited by 202
Neurotrophic Mechanisms in Drug Addiction
Bolaños, C. A., & Nestler, E. J. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:069 · Cited by 199
Progress in Parkinson's disease—Where do we stand?
Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 197
GDNF acutely modulates excitability and A-type K+ channels in midbrain dopaminergic neurons
Yang, F., Feng, L., Zheng, F., Johnson, S. W., Du, J., Shen, L., Wu, C.-P., & Lu, B. (2001) · Nature Neuroscience · doi:10.1038/nn734 · Cited by 193
Midbrain dopaminergic neurons: A review of the molecular circuitry that regulates their development
Hegarty, S. V., Sullivan, A. M., & O’Keeffe, G. W. (2013) · Developmental Biology · doi:10.1016/j.ydbio.2013.04.014 · Cited by 190
MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain
Lindholm, P., Peränen, J., Andressoo, J., Kalkkinen, N., Kokaia, Z., Lindvall, O., Timmusk, T., & Saarma, M. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.07.016 · Cited by 187
Glial Cell Line Derived Neurotrophic Factor Delays Photoreceptor Degeneration in a Transgenic Rat Model of Retinitis Pigmentosa
Sanftner, L. H. M., Abel, H., Hauswirth, W. W., & Flannery, J. G. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0498 · Cited by 191
Striatal and extrastriatal dopamine in the basal ganglia: An overview of its anatomical organization in normal and Parkinsonian brains
Smith, Y., & Villalba, R. M. (2008) · Movement Disorders · doi:10.1002/mds.22027 · Cited by 194
PHARMACOLOGY OF NEUROTROPHIC FACTORS
Hefti, F. F. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.239 · Cited by 186
Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.
Ramanan, V. K., & Saykin, A. J. (2013) · Europe PMC (PubMed Central) · Cited by 190
Lentiviral Vectors as a Gene Delivery System in the Mouse Midbrain: Cellular and Behavioral Improvements in a 6-OHDA Model of Parkinson's Disease Using GDNF
Bensadoun, J., Déglon, N., Tseng, J., Ridet, J., Zurn, A. D., & Aebischer, P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7409 · Cited by 183
Growth/Differentiation Factor-15/Macrophage Inhibitory Cytokine-1 Is a Novel Trophic Factor for Midbrain Dopaminergic NeuronsIn Vivo
Strelau, J., Sullivan, A. M., Bottner, M. B., Lingor, P., Falkenstein, E., Suter‐Crazzolara, C., Galter, D., Jászai, J., KRIEGLSTEIN, K. G., & Unsicker, K. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08597.2000 · Cited by 175
Unilateral intraputamenal glial cell line–derived neurotrophic factor in patients with Parkinson disease: Response to 1 year of treatment and 1 year of withdrawal
Slevin, J. T., Gash, D. M., Smith, C. D., Gerhardt, G. A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R., & Young, A. B. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.4.614 · Cited by 173
Self-citation
Differential Effects of Glial Cell Line‐Derived Neurotrophic Factor and Neurturin on Developing and Adult Substantia Nigra Dopaminergic Neurons
Åkerud, P., Alberch, J., Eketjäll, S., Wagner, J., & Arenas, E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730070.x · Cited by 171
Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains
Bartus, R. T., Herzog, C. D., Chu, Y., Wilson, A., Brown, L., Siffert, J. O., Johnson, E. M., Olanow, C. W., Mufson, E. J., & Kordower, J. H. (2010) · Movement Disorders · doi:10.1002/mds.23442 · Cited by 170
Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: A real-time PCR study
Bäckman, C. M., Shan, L., Zhang, Y. J., Hoffer, B. J., Leonard, S. S., Troncoso, J. C., Vonsatel, P., & Tomac, A. C. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.03.013 · Cited by 170
Self-citation
Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies
Ji, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., Zhang, M.-R., Suzuki, K., Ando, K., Staufenbiel, M., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2312-08.2008 · Cited by 169
The Scientific Basis for the Current Treatment of Parkinson's Disease
Olanow, C. W. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104422 · Cited by 169
Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates
Behrstock, S. P., Ebert, A. D., McHugh, J., Vosberg, S. K., Moore, J. M., Schneider, B. L., Capowski, E. E., Hei, D. J., Kordower, J. H., Aebischer, P., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302679 · Cited by 168
Glial Cell Line-derived Neurotrophic Factor Signals through the RET Receptor and Activates Mitogen-activated Protein Kinase
Worby, C. A., Vega, Q. C., Zhao, Y., Chao, H. H.-J., Seasholtz, A. F., & Dixon, J. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23619 · Cited by 167

Authors: Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., Hoffer, B. J., & Gerhard, G. A.
Affiliations: University of Kentucky (US)
ORCID: Gash, Don M.
Zhang, Zhiming
Cass, Wayne A.
Lapchak, Paul A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1996-03
Volume: 380
Issue: 6571
Pages: 252-255
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/380252a0
OpenAlex: W1971258758
Cited by: 955
References: 22
Citations by year: 2026: 2 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 20 · 2021: 16 · 2020: 23 · 2019: 18 · 2018: 20 · 2017: 13 · 2016: 21 · 2015: 27 · 2014: 24 · 2013: 30 · 2012: 27
FWCI: 51.18
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, glial cell line-derived neurotrophic factor, MPTP-induced parkinsonism, rhesus monkeys, dopaminergic neurons, midbrain dopamine, globus pallidus, nigral neurons, bradykinesia, rigidity, postural instability, functional recovery, neuroprotection, neurotrophic therapy
MeSH terms: Animals, Dopamine, Female, Humans, Macaca mulatta, Mesencephalon, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Recombinant Proteins, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Glial Cell Line-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functional recovery in parkinsonian monkeys treated with GDNF

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks